CVS Health stock gains as vaccines and Q2 beat support it

CVS Health Corp. (US1266501006) stock drew fresh interest after updated 2026-2027 COVID-19 vaccines became available at CVS Pharmacy and MinuteClinic locations across the United States, while the company also posted Q2 2026 EPS of USD 2.58 on revenue of USD 106.10 billion.

Vaccine rollout adds a catalyst

According to a Yahoo Finance report, CVS said the updated 2026-2027 COVID-19 shots are now available nationwide in its pharmacy and clinic network as of September 5, 2026. That gives the retail health business a visible near-term operating angle beyond the latest earnings release.

The same source said the company is offering appointments and walk-ins across the network, which matters because CVS uses its stores and clinics as the front end for consumer immunization traffic.

Q2 2026 sets the base

MarketBeat said CVS Health last reported quarterly EPS of USD 2.58 on August 5, 2026, ahead of the USD 1.87 consensus by USD 0.71, while revenue reached USD 106.10 billion, up 7.3 percent year over year.

MarketBeat also cited FY 2026 guidance of USD 7.90 to USD 8.10 EPS, and the same update said analysts on average see USD 8.02 EPS for the current fiscal year. That leaves the market focused on whether the second-half run rate can hold after the Q2 beat.

Retail health stays central

Simply Wall St described CVS as a company with about USD 412.6 billion in revenue, led by Health Services at about USD 200.5 billion, Health Care Benefits at USD 143.8 billion and Pharmacy and Consumer Wellness at USD 139.7 billion. That mix explains why vaccine activity and benefit economics can matter at the same time.

The operating spread is still tight: MarketBeat quoted a net margin of 1.18 percent and return on equity of 13.12 percent in the latest quarterly update, which means small changes in cost discipline can move the earnings picture quickly.

Stock near the top of its range

Robinhood showed CVS Health at USD 97.00 on September 5, 2026, with a market capitalization of USD 123.71 billion, a 52-week range of USD 69.51 to USD 110.68, and a daily range of USD 96.31 to USD 97.69. The stock was therefore trading above the session low and below the session high on the last completed trading day.

For investors, the key contrast is clear: a market value above USD 123 billion sits next to a margin profile that still leaves little room for disappointment.

What CVS sells

CVS Health's most visible consumer touchpoint remains the pharmacy and clinic network, now paired with the updated COVID-19 vaccine rollout across CVS Pharmacy and MinuteClinic locations. That is the business line most directly tied to the September 5, 2026 rollout news and to retail traffic in the near term.

Price and range

CVS Health stock stood at USD 97.00 as of September 5, 2026. Robinhood put the 52-week range at USD 69.51 to USD 110.68, with market capitalization at USD 123.71 billion.